Gameto Highlights Late-Stage Fertility Program, ARPA-H–Backed Menopause Therapy and $127 Million in Funding

Gameto has shared an update. The company highlighted a media profile featuring CEO and Co-Founder Dina Radenkovic Turner and Chief Scientific Officer Christian Kramme, which outlines its pipeline in women’s health, including fertility, menopause, and ovarian disease. Gameto reported that Fertilo, its IVF-focused platform, is in final Phase 3 trials, has contributed to nine births, and has received several regulatory approvals, signaling late-stage clinical progress in a key product candidate. The company also noted Ameno, a next-generation cell therapy for menopause backed by a $10 million ARPA-H grant and preparing to enter clinical trials, as well as Deovo, a platform aimed at improving research and drug testing in ovarian disease. Gameto disclosed that its Series C round, led by Kristina Simmons of Overwater Ventures, brought total funding to $127 million.

For investors, the update underscores a maturing clinical and financing profile. Fertilo’s advancement to final Phase 3 trials and initial regulatory approvals may shorten the timeline to potential commercialization in parts of the IVF market, which could create a future revenue stream if trial outcomes and broader approvals are favorable. The ARPA-H grant for Ameno reduces early development risk and validates the scientific premise in menopause care, a large, underserved segment with significant long-term revenue potential if efficacy and safety are demonstrated. Deovo’s focus on ovarian disease research tools suggests an additional, possibly platform-based revenue opportunity, though timelines and monetization models are less defined. The completed Series C and cumulative $127 million in funding strengthen Gameto’s balance sheet for near-term R&D and clinical activities, but investors should note the company remains in a pre-commercial biopharma stage, with value still highly dependent on clinical results, regulatory pathways, and eventual adoption in fertility and women’s health markets.